Injectable cryogel vaccine devices and methods of use thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/70
A61K-047/36
A61K-047/42
A61K-039/39
A61K-009/00
A61K-039/00
A61L-027/26
A61L-027/50
A61L-027/54
A61L-027/56
출원번호
US-0166689
(2014-01-28)
등록번호
US-9675561
(2017-06-13)
발명자
/ 주소
Bencherif, Sidi A.
Sands, Roger Warren
Koshy, Sandeep T.
Mooney, David J.
출원인 / 주소
President and Fellows of Harvard College
대리인 / 주소
Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
인용정보
피인용 횟수 :
1인용 특허 :
41
초록
The invention provides polymer compositions for cell and drug delivery.
대표청구항▼
1. An injectable device comprising a cell-adhesive, highly crosslinked cryogel composition comprising open interconnected macropores, wherein said cryogel composition comprises at least 75% pores,wherein said cryogel composition is characterized by shape memory following deformation by compression t
1. An injectable device comprising a cell-adhesive, highly crosslinked cryogel composition comprising open interconnected macropores, wherein said cryogel composition comprises at least 75% pores,wherein said cryogel composition is characterized by shape memory following deformation by compression through a needle,wherein said cryogel composition comprises a crosslinked gelatin polymer, wherein said gelatin is methacrylated,wherein said cryogel composition comprises a methacrylated gelatin concentration of 0.5% to 1.4% (w/v), andwherein said cryogel composition comprises a live attenuated breast cancer cell in one or more of said open interconnected pores. 2. The device of claim 1, wherein the device recruits cells into the cryogel composition upon injection into a subject. 3. The device of claim 2, wherein the cryogel composition is degraded by the recruited cells. 4. The device of claim 1, wherein the cryogel composition is formed by cryopolymerization of methacrylated gelatin. 5. The device of claim 4, wherein the cryogel composition further comprises a methacrylated alginate macromonomer. 6. The device of claim 1, wherein said cryogel composition comprises a biomolecule in one or more of said open interconnected pores. 7. The device of claim 6, wherein said biomolecule comprises a small molecule, nucleic acid, or protein. 8. The device of claim 7, wherein said protein comprises granulocyte-macrophage colony-stimulating factor (GM-CSF). 9. The device of claim 7, wherein said nucleic acid comprises a CpG nucleic acid oligonucleotide (CpG-ODN). 10. The device of claim 1, wherein the device is between 100 um3 to 100 mm3 in size. 11. A method for eliciting an immune response, comprising injecting the device of claim 1 into a subject, wherein an immune response is elicited against the live attenuated breast cancer cell. 12. The method of claim 11, wherein the device is injected into the subject one to 5 times in the lifetime of the subject. 13. The method of claim 11, wherein the injected device comprises at least 0.5×106 immune cells at least 1 day after injection into the subject. 14. The method of claim 11, wherein the injected device comprises 107 or fewer cells 15 days or more after injection. 15. The method of claim 11, wherein the injected device, a tissue within 10 cm of the injected device, or both comprises an elevated level of a cytokine compared to the level of the cytokine at a site in the subject more than 10 cm away from the injected device. 16. The method of claim 11, wherein the device increases the survival time of at least 80% of subjects diagnosed with a cancer by at least 1 month compared to the survival time of untreated subjects, wherein increased survival time is determined by comparing the prognosis for survival in the subjects from a time period prior to administration of the device to the prognosis for survival in the subjects following administration of the device, wherein an increase in predicted survival time indicates that the treatment increased survival of the subjects following administration of the device. 17. The method of claim 11, wherein the device reduces the rate of tumor growth in the subject compared to the rate of tumor growth in an untreated subject. 18. The device of claim 7, wherein said nucleic acid comprises deoxyribonucleic acid (DNA). 19. The device of claim 1, wherein the device is in the shape of a disc, cylinder, square, rectangle, or string. 20. The device of claim 1, wherein said highly crosslinked cryogel composition comprises a crosslinking density of at least 50% polymer crosslinking. 21. The device of claim 1, wherein said highly crosslinked cryogel composition comprises a crosslinking density of at least 50-100% polymer crosslinking. 22. The device of claim 1, wherein said device comprises live attenuated HER-2/neu expressing breast cancer cells. 23. The device of claim 1, wherein said live attenuated breast cancer cell is an irradiated breast cancer cell. 24. The device of claim 1, wherein said cryogel composition comprises macropores having a diameter of 20 μm to 300 μm. 25. A syringe comprising an injectable device comprising a cell-adhesive, highly crosslinked cryogel composition comprising open interconnected pores, wherein said cryogel composition comprises at least 75% pores,wherein said cryogel composition is characterized by shape memory following deformation by compression,wherein said cryogel composition comprises a crosslinked gelatin polymer, wherein said gelatin is methacrylated,wherein said cryogel composition comprises a methacrylated gelatin concentration of 0.5% to 1.4% (w/v), andwherein said cryogel composition comprises live attenuated breast cancer cells in one or more of said open interconnected pores. 26. The syringe of claim 25, comprising a 16-gauge, an 18-gauge, a 22-gauge, a 24-gauge, a 26-gauge, a 28-gauge, a 30-gauge, a 32-gauge, or a 34-gauge needle. 27. The syringe of claim 25, comprising an 18 to 30-gauge needle. 28. The syringe of claim 26, wherein the device is between 1 mm3 to 50 mm3 in size. 29. The syringe of claim 26, wherein 90% or more of the cancer cells survive passage of the device through the bore of the needle. 30. The syringe of claim 25, wherein said cryogel composition is characterized by shape memory following deformation by compression through a needle, such that said cryogel returns to its original undeformed three-dimensional shape less than one second after compression through the needle. 31. The syringe of claim 25, wherein said cryogel composition comprises macropores having a diameter of 20 μm to 300 μm. 32. The method of claim 11, wherein the device (i) comprises live attenuated HER-2/neu expressing breast cancer cells, and(ii) increases the level of HER-2/neu-specific IgG antibody in subjects diagnosed with a cancer by approximately 70-fold compared to untreated subjects. 33. The device of claim 1, wherein said cryogel composition is characterized by shape memory following deformation by compression through a needle such that said cryogel composition returns to its original undeformed three-dimensional shape less than one second after compression through the needle. 34. The device of claim 6, wherein said biomolecule comprises a pathogen-associated molecular pattern (PAMP). 35. An injectable device comprising a cell-adhesive, highly crosslinked cryogel composition comprising open interconnected macropores, wherein said cryogel composition comprises at least 75% pores,wherein said cryogel composition is characterized by shape memory following deformation by compression through a needle,wherein said cryogel composition comprises a crosslinked gelatin polymer, wherein said gelatin is methacrylated, andwherein said cryogel composition comprises a methacrylated gelatin concentration of 0.5% to 1.4% (w/v). 36. The device of claim 35, wherein said cryogel composition comprises macropores having a diameter of 20 μm to 300 μm. 37. The device of claim 35, wherein said cryogel composition is characterized by shape memory following deformation by compression through a needle, such that said cryogel returns to its original undeformed three-dimensional shape less than one second after compression through the needle. 38. The device of claim 35, wherein said highly crosslinked cryogel composition comprises a crosslinking density of at least 50-100% polymer crosslinking. 39. A syringe comprising the device of claim 35.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (41)
Huston James S. (Chestnut Hill MA) Oppermann Hermann (Medway MA), Biosynthetic antibody binding sites.
Pardoll Drew ; Azhari Rosa,ILX ; Leong Kam W. ; Golumbe Paul K ; Jaffee Elizabeth ; Levitsky Hyam ; Lazenby Audrey, Controlled release of pharmaceutically active substances for immunotherapy.
Gaur Amitabh ; Conlon Paul ; Ling Nicholas C. ; Staehelin Theophil,CHX ; Crowe Paul D., Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein.
Murphy, William L.; Mooney, David J.; Kohn, David H.; Spalding, Gabriel C.; Dearing, Matthew T., Mineral and cellular patterning on biomaterial surfaces.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
Hackam, David J.; Gribar, Steven C., Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.